Cardiff Oncology is a clinical-stage biotech firm based in San Diego that develops cancer treatments, with its primary focus on Onvansertib, an oral medication targeting polo-like kinase 1 for use in RAS-mutated colorectal cancer. The company is advancing several clinical trials evaluating Onvansertib alone and in combination with standard chemotherapy regimens across colorectal cancer and other tumor types including pancreatic, lung, breast, and blood cancers. Founded in 1999 and formerly known as Trovagene, the company is currently investigating whether this approach can benefit patients with specific genetic mutations.
1Y: 0.89 (-62.1%) · range 0.80–3.21
entry readiness 78 · GOOD SETUP · exit proximity 0
Value area 0.76–1.40 · 83% of 120d volume overhead · heavy supply
No source detections in the last 21 days.
| Horizon | Return | MFE | State |
|---|---|---|---|
| 20d | -34.11% | +4.65% | mature |
| 40d | -23.26% | +4.65% | mature |